NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY – Get Rating) in a report issued on Thursday. The brokerage set a “hold” rating on the stock.

NovaBay Pharmaceuticals Stock Performance

NYSE:NBY opened at $0.70 on Thursday. NovaBay Pharmaceuticals has a 1 year low of $0.48 and a 1 year high of $12.64.

Get NovaBay Pharmaceuticals alerts:

NovaBay Pharmaceuticals Company Profile

(Get Rating)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.

See Also

• Get a free copy of the StockNews.com research report on NovaBay Pharmaceuticals (NBY)
• Game-Changing News For AMD And Its Shareholders
• How to Read Stock Charts for Beginners
• Can Chegg’s AI Pivot Save It From Disruption?
• Best Investment Strategy in 2023: Determine the Right One for You
• Enovix: A Rising Power in the Lithium-Ion Industry

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.